Unknown

Dataset Information

0

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.


ABSTRACT: To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes.Sixteen subjects with type 2 diabetes (age 59.8 ± 6.8 years, BMI 29.1 ± 4.8 kg/m(2), HbA(1c) 6.97 ± 0.61) on oral blood glucose-lowering treatment were included. Participants received vildagliptin 50 mg b.i.d. or acarbose 100 mg t.i.d. for four consecutive weeks in a randomized, double-blind, cross-over design. At the end of each treatment period, we measured forearm vasodilator responses to intra-arterially administered acetylcholine (endothelium-dependent vasodilator) and sodium nitroprusside (endothelium-independent vasodilator).Infusion of acetylcholine induced a dose-dependent increase in forearm blood flow in the experimental arm, which was higher during vildagliptin (3.1 ± 0.7, 7.9 ± 1.1, and 12.6 ± 1.4 mL ? dL(-1) ? min(-1) in response to three increasing dosages of acetylcholine) than during acarbose (2.0 ± 0.7, 5.0 ± 1.2, and 11.7 ± 1.6 mL ? dL(-1) ? min(-1), respectively; P = 0.01 by two-way ANOVA). Treatment with vildagliptin did not significantly change the vascular responses to sodium nitroprusside.Four weeks' treatment with vildagliptin improves endothelium-dependent vasodilatation in subjects with type 2 diabetes. This observation might have favorable cardiovascular implications.

SUBMITTER: van Poppel PC 

PROVIDER: S-EPMC3161271 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Vildagliptin improves endothelium-dependent vasodilatation in type 2 diabetes.

van Poppel Pleun C M PC   Netea Mihai G MG   Smits Paul P   Tack Cees J CJ  

Diabetes care 20110725 9


<h4>Objective</h4>To investigate whether the dipeptidyl peptidase-4 inhibitor vildagliptin improves endothelium-dependent vasodilatation in patients with type 2 diabetes.<h4>Research design and methods</h4>Sixteen subjects with type 2 diabetes (age 59.8 ± 6.8 years, BMI 29.1 ± 4.8 kg/m(2), HbA(1c) 6.97 ± 0.61) on oral blood glucose-lowering treatment were included. Participants received vildagliptin 50 mg b.i.d. or acarbose 100 mg t.i.d. for four consecutive weeks in a randomized, double-blind,  ...[more]

Similar Datasets

| S-EPMC2924465 | biostudies-literature
| S-EPMC5972298 | biostudies-literature
| S-EPMC2630874 | biostudies-literature
| S-EPMC7906977 | biostudies-literature
| S-EPMC2438989 | biostudies-other
| S-EPMC3575784 | biostudies-literature
| S-EPMC6912967 | biostudies-literature
| S-EPMC4550051 | biostudies-literature
| S-EPMC2951430 | biostudies-literature
| S-EPMC3889317 | biostudies-literature